Back to state act
Description
On 29 July 2020, the Norwegian Medicines Agency introduced an export ban on rivaroxaban, apixaban, certain immunoglobulins and palivizumab. The export ban was introduced due to concerns of shortages f...
Sign in to see full description
Intervention Details
Intervention Type
Export ban
MAST Chapter
P: Export-related measures (incl. subsidies)
Implementation date
29 Jul 2020
Revocation date
28 Jan 2021
Implementation level
National
Affected flow
Outward
Announced as temporary
Yes
Eligible firms
all
Affected Trading Partners
Table
Affected Sectors
Sign in to access 1 sectors
Affected Products
Sign in to access 6 products
Threads
See all
This intervention is not part of any Thread yet.